(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Georgetown University
ETOP IBCSG Partners Foundation
Novartis
Blueprint Medicines Corporation
First Affiliated Hospital of Zhejiang University
The Netherlands Cancer Institute
Daiichi Sankyo